Core Viewpoint - Pasithea Therapeutics is presenting its lead program, Basel IV, which is the first macrocyclic MEK inhibitor to enter clinical trials, highlighting its differentiated profile in terms of safety, pharmacokinetics, and early signs of efficacy [3]. Company Overview - Pasithea Therapeutics is participating in Oppenheimer's 36th Annual Life Sciences Conference, showcasing its innovative approach in the biotech sector [1]. - The CEO of Pasithea, Tiago Reis Marques, emphasizes the company's commitment to advancing its clinical programs despite personal health challenges [2]. Product Focus - The lead program, Basel IV, targets neurofibromas associated with neurofibromatosis type 1, specifically focusing on plexiform neurofibromas and cutaneous neurofibromas [3]. - The presentation will include data supporting the safety and pharmacokinetic profile of Basel IV, as well as early efficacy results in monotherapy [3].

Core Viewpoint - Pasithea Therapeutics Corp. is advancing its clinical trials for PAS-004, a macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 associated plexiform neurofibromas and advanced cancer, with significant milestones achieved in 2025 [1][3]. Clinical Trials - The ongoing Phase 1/1b clinical trial for adult patients with NF1-PN (NCT06961565) is part of the company's strategy to develop PAS-004 [2]. - The Phase 1 clinical trial in advanced cancer patients (NCT06299839) is expected to present longer-term follow-up data in Q2 2026, with initial promising results reported in 2025 [3][4]. - Enrollment of 12 patients has been completed through the first four dose cohorts in the NF1-PN study, with data presentation planned for the second half of 2026 [6]. Financial Developments - In December 2025, the company raised $60 million in gross proceeds through a public offering, which will support the advancement of PAS-004 and operations through at least the first half of 2028 [3]. Drug Development Insights - Initial results from the advanced cancer study indicated a partial response and a disease control rate of 71.4% among patients with BRAF-mutated tumors, supporting the potential of PAS-004 for NF1-PN treatment [3]. - The company aims to deliver safe and effective therapies for patients with significant unmet medical needs, particularly in chronic dosing scenarios [3].